Table 2.
Surgery, chemotherapy, treatment response, and follow-up duration.
| Treatment Characteristics, Response and Follow-Up | Total Sample (n = 43) |
HR Group (n = 26) |
SR Group (n = 14) |
Ex-Infant (n = 3) |
||||
|---|---|---|---|---|---|---|---|---|
| Extent of resection | ||||||||
| Partial | 20 (46.5%) | 15 (57.7%) | 2 (14.3%) | 3 (100.0%) | ||||
| Near-total | 2 (4.7%) | - | 2 (14.3%) | - | ||||
| Gross-total | 21 (48.8%) | 11 (42.3%) | 10 (71.4%) | - | ||||
| HD-CHT with aHSCT prior to PT | 14 (32.6%) | 11 (42.3%) | - | 3 (100.0%) | ||||
| Concomitant CHT to PT | 18 (41.9%) | 13 (50.0%) | 5 (35.7%) | - | ||||
| Treatment response | ||||||||
| CR | 35 (81.4%) | 20 (76.9%) | 12 (85.7%) | 3 | 100.0% | |||
| SD | 3 (7.0%) | 3 (11.5%) | - | - | - | |||
| PD | 5 (11.6%) | 3 (11.5%) | 2 (14.2%) | - | - | |||
| Survival at latest FU | ||||||||
| Alive | 41 (95.3%) | 24 (92.3%) | 14 (100.0%) | 3 | 100.0% | |||
| Dead | 2 (4.7%) | 2 (7.7%) | - | - | - | |||
| Median (IQR) | Min–Max | Median (IQR) | Min–Max | Median (IQR) | Min–Max | Median (IQR) | Min–Max | |
| FU duration, months | 26.0 (30.5) | 2.0–67.0 | 20.0 (31.3) | 5.0–67.0 | 28.5 (22.8) | 2.0–66.0 | 24.0 (21.5) | 3.0–46.0 |
HD-CHT: high-dose chemotherapy; aHSCT: autologous hematopoietic stem-cell transplantation; PT: proton therapy; CHT: chemotherapy; CR: complete response; SD: stable disease; PD: progressive disease; FU: follow-up.